[ad_1]
Pfizer’s coronavirus vaccine is 95 percent effective and has passed its safety checks, according to other company data.
The pharmaceutical giant and its partner BioNTech released interim results last week showing that the jab could prevent more than 90 percent of people from developing Covid-19.
That data was based on the first 94 volunteers to develop Covid-19, but additional figures released Wednesday are based on the first 170 cases of the virus in the clinical trial.
The vaccine has been tested in 43,500 people in six countries and no safety concerns have been raised.
Another vaccine, from the American company Moderna, showed this week in the first data that it is almost 95 percent effective.
The results of a vaccine study from the University of Oxford and AstraZeneca are expected soon.
Reply
The Pfizer vaccine has been shown to produce an antibody and T-cell response in the body to fight the coronavirus.
Pfizer and BioNTech expect to be able to produce up to 50 million doses of vaccines globally in 2020 and up to 1.3 billion in 2021.
On Tuesday, Pfizer CEO Albert Bourla said the company is preparing to apply for an emergency use authorization from the US Food and Drug Administration – PA.
[ad_2]